US 7320991
Analogs of thalidomide as potential angiogenesis inhibitors
granted A61KA61K31/4035A61K31/454
Quick answer
US patent 7320991 (Analogs of thalidomide as potential angiogenesis inhibitors) held by The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer expires Mon Jan 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer
- Grant date
- Tue Jan 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/4035, A61K31/454, A61K31/506, A61K31/513